Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis.

Mannose-binding lectin (MBL) is a key factor in innate immunity, and lung infections are the leading cause of morbidity and mortality in cystic fibrosis (CF). Accordingly, we investigated whether MBL variant alleles, which are associated with recurrent infections, might be risk factors for CF patients. In 149 CF patients, different MBL genotypes were compared with respect to lung function, microbiology, and survival to end-stage CF (death or lung transplantation). The lung function was significantly reduced in carriers of MBL variant alleles when compared with normal homozygotes. The negative impact of variant alleles on lung function was especially confined to patients with chronic Pseudomonas aeruginosa infection. Burkholderia cepacia infection was significantly more frequent in carriers of variant alleles than in homozygotes. The risk of end-stage CF among carriers of variant alleles increased 3-fold, and the survival time decreased over a 10-year follow-up period. Moreover, by using a modified life table analysis, we estimated that the predicted age of survival was reduced by 8 years in variant allele carriers when compared with normal homozygotes. Presence of MBL variant alleles is therefore associated with poor prognosis and early death in patients with CF.

[1]  V. Guess.  Pulmonary Function Testing in Children: Techniques and Standards , 1972 .

[2]  W. Warwick,et al.  Survival patterns in cystic fibrosis , 1975 .

[3]  L. Jacobsen,et al.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. , 1977, Scandinavian journal of respiratory diseases.

[4]  N. Høiby.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. , 1977, Acta pathologica et microbiologica Scandinavica. Supplement.

[5]  G. Döring,et al.  Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. , 1986, The American review of respiratory disease.

[6]  Aileen B. Sedman,et al.  A longitudinal study , 1987 .

[7]  R. Ezekowitz,et al.  A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins [published erratum appears in J Exp Med 1991 Sep 1;174(3):753] , 1988, The Journal of experimental medicine.

[8]  Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. , 1989 .

[9]  C. Morton,et al.  The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10 , 1989, The Journal of experimental medicine.

[10]  M. Taylor,et al.  Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. , 1989, The Biochemical journal.

[11]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[12]  M. Schwartz,et al.  Frequency of the delta F508 mutation on cystic fibrosis chromosomes in Denmark. , 1990, Human genetics.

[13]  R. Levinsky,et al.  Molecular basis of opsonic defect in immunodeficient children , 1991, The Lancet.

[14]  M. Schwartz,et al.  Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation , 1991, The Lancet.

[15]  T. Fujita,et al.  Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease , 1992, The Journal of experimental medicine.

[16]  N. Høiby,et al.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. , 1992, Thorax.

[17]  Y. Lau,et al.  High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. , 1992, Human molecular genetics.

[18]  S. Thiel,et al.  DIALLELIC POLYMORPHISM MAY EXPLAIN VARIATIONS OF THE BLOOD CONCENTRATION OF MANNAN‐BINDING PROTEIN IN ESKIMOS, BUT NOT IN BLACK AFRICANS , 1992, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[19]  S. Thiel,et al.  Mannan‐binding protein—levels in plasma and upper‐airways secretions and frequency of genotypes in children with recurrence of otitis media , 1993, Clinical and experimental immunology.

[20]  N. Høiby,et al.  Pathogenesis of cystic fibrosis , 1993, The Lancet.

[21]  Š. Kaluz,et al.  Assignment of the human pulmonary surfactant protein D gene (SFTP4) to 10q22-q23 close to the surfactant protein A gene cluster. , 1993, Genomics.

[22]  A. Svejgaard,et al.  DUAL ROLE OF MANNAN‐BINDING PROTEIN IN INFECTIONS: ANOTHER CASE OF HETEROSIS? , 1994, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[23]  S. Thiel,et al.  Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. , 1995, Journal of immunology.

[24]  A. Svejgaard,et al.  Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency , 1995, The Lancet.

[25]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[26]  M. Turner,et al.  Mannose binding protein gene mutations associated with unusual and severe infections in adults , 1995, The Lancet.

[27]  W. Thomson,et al.  Mannose-binding protein gene polymorphism in systemic lupus erythematosus. , 1995, Arthritis and rheumatism.

[28]  S. Sheriff,et al.  The collectins in innate immunity. , 1996, Current opinion in immunology.

[29]  P. Vandamme,et al.  Burkholderia cepacia: medical, taxonomic and ecological issues. , 1996, Journal of medical microbiology.

[30]  B. Frederiksen,et al.  Improved survival in the Danish center‐treated cystic fibrosis patients: Results of aggressive treatment , 1996, Pediatric pulmonology.

[31]  E. Greenberg,et al.  Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid , 1996, Cell.

[32]  M. Turner,et al.  Mannose-binding lectin: the pluripotent molecule of the innate immune system. , 1996, Immunology today.

[33]  M. Petri,et al.  Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[34]  W. Ollier,et al.  A dysfunctional allele of the mannose binding protein gene associates with systemic lupus erythematosus in a Spanish population. , 1997, The Journal of rheumatology.

[35]  A. Svejgaard,et al.  Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin , 1997, The Lancet.

[36]  L. Morey,et al.  Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice , 1997, Journal of virology.

[37]  A second serine protease associated with mannan-binding lectin that activates complement , 1997 .

[38]  G. Pier,et al.  Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Coggon,et al.  Prospective cohort study of predictors of incident low back pain in nurses , 1997, BMJ.

[40]  M. Griese,et al.  Pulmonary surfactant in cystic fibrosis. , 1997, The European respiratory journal.

[41]  A. Henschen-Edman,et al.  cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. , 1997, Immunity.

[42]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[43]  S. Chanock,et al.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. , 1998, The Journal of clinical investigation.

[44]  B. Høgh,et al.  Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. , 1998, Journal of immunology.

[45]  N. Graudal,et al.  Mannan binding lectin in rheumatoid arthritis. A longitudinal study. , 1998, The Journal of rheumatology.

[46]  M. Moustaki,et al.  Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. , 1999, American journal of respiratory cell and molecular biology.